Cautious. Zebra Bio's 26/100 Value Compounder Score reflects early-stage biotech economics with unproven unit economics and high cash burn. Leadership Alignment at 52.3/100 suggests moderate founder-CEO conviction, but the Vulnerability Index at 100/100 signals acute structural risk—likely clinical trial execution dependency, rare-disease market constraints, or limited regulatory pathway visibility. Investors should await Phase 2/3 efficacy data and capital runway clarity before reassessing.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Zenas BioPharma, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 43/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Zenas BioPharma, Inc. (ZBIO) at 43/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Zebra Bio's 26/100 Value Compounder Score reflects early-stage biotech economics with unproven unit economics and high cash burn. Leadership Alignment at 52.3/100 suggests moderate founder-CEO conviction, but the Vulnerability
ZBIO's current Stocky Verdict is 43/100, placing it in the "Cautious" band. This composite combines a 26/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Zenas BioPharma, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Zenas BioPharma, Inc. scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Zenas BioPharma, Inc.'s Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Zenas BioPharma, Inc..
Sign up free and unlock the full analysis on ZBIO — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for ZBIO in the app.
